At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 125 enrolled
Drug / intervention
30 ml of 0.2% ropivacaine +3 moredrug
Likely dose
30 ml of 0.2% ropivacainefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Outcome Following Arthroscopic Knee Surgery (COFAKS)-Addendum
The University of Texas Health Science Center, Houston·interventional·Posted Oct 12, 2018·Updated Oct 21, 2021
In Brief
A Phase 4 clinical trial evaluating 30 ml of 0.2% ropivacaine, 15 ml of 0.2% ropivacaine, and 2 other interventions for Anterior Cruciate Ligament Injury. Completed, enrolled 125 participants across 1 site.
Detailed Summary
This study will examine the potential differences between femoral nerve blockade (FNB) and adductor canal blockade (ACB) for pain control and quadriceps muscle activation for patients following anterior cruciate ligament (ACL) reconstruction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnterior Cruciate Ligament Injury
CountriesUnited States
CollaboratorsMemorial Hermann Hospital
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartFeb 2016
Primary CompletionNov 2017
First PostedOct 2018
TodayJul 2026
First PostedOct 12, 2018
Enrollment StartFeb 1, 2016
Primary CompletionNov 16, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.7 years ago
Interventions
30 ml of 0.2% ropivacainedrug
15 ml of 0.2% ropivacainedrug
100 mcg clonidinedrug
High-frequency linear ultrasound transducerdevice